Business Wire

Cyble Launches Defense Threat Intelligence Solution for Law Enforcement and Government Agencies

Share

Cyble, an AI-powered, Y Combinator-backed, cyber threat intelligence company that empowers organizations with darkweb & cybercrime monitoring, today announced the availability of its Law Enforcement Agency (LEA) and defense threat intelligence solution. This is aimed at specifically helping law enforcement and government agencies gather, analyze, and respond to the exposure of extremely sensitive information, enriched with Cyble’s SIGINT analysis and research, that may have implications for national security or geopolitical ramifications. In this regard, Cyble has been working with several law enforcement agencies across the world.

Over the past few years, organized cybercriminals and state-backed threat actors have been actively targeting critical national infrastructure. Recent examples of this include the ransomware attack on the Colonial Pipeline in the US, which threatened to knock out fuel supply to half of the country.

Countries worldwide have seen their governments and military networks being hacked and troves of sensitive data exfiltrated by state-backed and financially motivated adversaries. The threat here is two-fold. Threat Actors primarily target organizations designated as Critical Information Infrastructure (CII) such as power plants, nuclear installations, oil pipelines and refineries, telecom network providers, and transport networks.

Additionally, threat actors are also targeting the supply chain eco-system of these organizations, which typically comprise technology OEMs, contract manufacturers, strategic R&D partners, and IT service providers. These attacks are carried out with an explicit intent of espionage, sabotage, as well as intellectual property theft.

Manish Chachada, Co-founder and COO of Cyble says, “As Cyble continues on its journey to empower more organizations with early threat intelligence, strategic collaborations like these play a key role. With an exponential increase in cyber-attacks as more organizations and agencies go digital, we aim to empower our government partners with advanced threat monitoring capabilities to provide expeditious intelligence which they can immediately act upon.”

Through Cyble Hawk, Cyble is now offering deep visibility into the darkweb and surface web to unearth attacks and discover sensitive information before it can be used to compromise state infrastructure, jeopardize national security, or cause diplomatic issues for governments.

Government agencies will now be empowered to hunt for and discover sensitive strategic information that could be used to avert financial fraud, detect sensitive or strategic data exposure, and deploy suitable countermeasures. Further details on the capabilities are available here.

“Cyble is excited to be collaborating with law enforcement and governmental agencies in helping them build a more resilient cyberspace presence, by empowering them with timely and actionable threat intelligence. As we expand our relationship to the government and LEA entities, we are thrilled to drive our research and intelligence capabilities to greater heights,” says Beenu Arora, Co-founder and CEO of Cyble.

About Cyble:

Cyble is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the darkweb. Its prime focus is to provide organizations with real-time visibility to their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Start-ups to Watch. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Medha Roy Chowdhury
EMAIL:Enquiries@Cyble.com
MOBILE: +1 678 379 3241

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye